6-chloro-N-(4-methoxyphenyl)-N'-phenyl-1,3,5-triazine-2,4-diamine | 101119-13-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-chloro-N-(4-methoxyphenyl)-N'-phenyl-1,3,5-triazine-2,4-diamine
• 英文别名: 2-Anilino-4-chlor-6-<4-methoxy-anilino>-s-triazin；6-chloro-N²-(4-methoxy-phenyl)-N⁴-phenyl-[1,3,5]triazine-2,4-diamine；6-Chloro-N-(4-methoxyphenyl)-N'-phenyl-[1,3,5]triazine-2,4-diamine；6-chloro-2-N-(4-methoxyphenyl)-4-N-phenyl-1,3,5-triazine-2,4-diamine
• CAS: 101119-13-5
• 化学式: C₁₆H₁₄ClN₅O
• 分子量: 327.773
• InChiKey: NKGYXZRIQYAHCR-UHFFFAOYSA-N

物化性质

• 沸点：
  542.7±52.0 °C(Predicted)
• 密度：
  1.382±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  72
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  6-chloro-N-(4-methoxyphenyl)-N'-phenyl-1,3,5-triazine-2,4-diamine 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.07h， 生成 2-N-(4-methoxyphenyl)-4-N-phenyl-6-N-{2-[(2-{10β-dihydroartemisinoxy}ethyl)amino]ethyl}-1,3,5-triazine-2,4,6-triamine
  参考文献：
  名称：

  Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin–triazine hybrids and hybrid-dimers

  摘要：

  A series of artemisinin-triazine hybrids and hybrid-dimers were synthesized and their in vitro antimalarial activity against the chloroquine sensitive (CQS), the gametocytocidal (NF54) and the choroquine resistant (CQR) Dd2 strains of Plasmodium falciparum determined, while their toxicity against CHO cells were also established. These compounds were prepared by linking artemisinin and triazine pharmacophores through nucleophilic substitution, using conventional and microwave assisted methods. These hybrids and hybrid-dimers were all found to be active against all three Plasmodium strains, with the p-anisidino-substituted triazine hybrid-dimer 22 being the most active of all. It showed good anti-gametocytocidal activity against the NF54 strain, with a 50% inhibitory concentration value in the nanomolar range, while having a potency comparable to that of artesunate against the Dd2 strain. This hybrid-dimer further demonstrated selective toxicity towards the parasitic cells. This dimer hence showed the necessary potential as candidate for further investigation in the search for malaria transmission blocking drugs so desperately needed. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.040
• 作为产物：
  描述：

  4,6-dichloro-N-(4-methoxyphenyl)-1,3,5-triazin-2-amine 在 N,N-二异丙基乙胺 、 苯胺 作用下， 以 乙酸乙酯 、 乙腈 为溶剂， 以57%的产率得到6-chloro-N-(4-methoxyphenyl)-N'-phenyl-1,3,5-triazine-2,4-diamine
  参考文献：
  名称：

  LPAAT-B inhibitors and uses thereof

  摘要：

  该发明涉及三嗪类化合物及其用于抑制溶磷脂酸酰基转移酶β（LPAAT-β）活性的用途。该发明还涉及使用这些三嗪类化合物治疗癌症的方法。该发明还涉及筛选LPAAT-β活性的方法。

  公开号：

  US20020103195A1

文献信息

• LPAAT-beta inhibitors and uses thereof
  申请人：Cell Therapeutics, Inc.

  公开号：US20030100557A1

  公开（公告）日：2003-05-29

  The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.

  本发明涉及三嗪类化合物及其用于抑制溶血磷脂酸酰转移酶β（LPAAT-β）活性的用途。本发明还涉及使用所述三嗪类化合物治疗癌症的方法。本发明还涉及筛选LPAAT-β活性的方法。
• LPAAT-β inhibitors and uses thereof
  申请人：Cell Therapuetics, Inc.

  公开号：US07199238B2

  公开（公告）日：2007-04-03

  The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.

  本发明涉及三嗪类化合物及其用于抑制溶血磷脂酸酰转移酶β（LPAAT-β）活性的应用。本发明还涉及使用该三嗪类化合物治疗癌症的方法。本发明还涉及筛选LPAAT-β活性的方法。
• LPAAT-BETA INHIBITORS AND USES THEREOF
  申请人：BONHAM Lynn

  公开号：US20100189726A1

  公开（公告）日：2010-07-29

  The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.

  该发明涉及三嗪及其用于抑制溶血磷脂酸酰转移酶β（LPAAT-β）活性的用途。该发明还涉及使用该三嗪治疗癌症的方法。该发明还涉及筛选LPAAT-β活性的方法。
• Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives
  作者：Mingfang Zheng、Chenghui Xu、Jianwei Ma、Yan Sun、Feifei Du、Hong Liu、Liping Lin、Chuan Li、Jian Ding、Kaixian Chen、Hualiang Jiang

  DOI：10.1016/j.bmc.2006.11.028

  日期：2007.2

  A series of triaminotriazine derivatives (compounds 5a-f, 6a-x, and 7a-g) was designed, synthesized, and evaluated for their inhibition activities to colorectal cancer (CRC) cell lines (HCT-116 and HT-29). Most of the synthesized compounds demonstrated moderate anti-proliferatory effects on both HCT-116 and HT-29 cell lines at the concentration of 10 mu M. The inhibitory activities against HCT-116 and HT-29 cell lines were discussed to develop the structure-activity relationships of this new series. Compounds 61 and 6o exhibited prominent inhibition activities toward HCT-116, with IC50S of 0.76 and 0.92 mu M, respectively. The in vivo antitumor studies and pharmacokinctics of compound 61 showed that it might be a promising new hit for further development of antitumor agents. (c) 2006 Elsevier Ltd. All rights reserved.
• US7064125B2
  申请人：——

  公开号：US7064125B2

  公开（公告）日：2006-06-20